LIVE
LIVE GMP
Watrana Rentals Ltd₹0·Crystal Crop Protection Ltd₹+45·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·M.K.Sons Fine Jewels Ltd₹+3·Watrana Rentals Ltd₹0·Crystal Crop Protection Ltd₹+45·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·M.K.Sons Fine Jewels Ltd₹+3·
Bio Medica Laboratories Ltd
CLOSED
BSE SME
Bookbuilding IPO
Fresh capital cum OFS
Bio Medica Laboratories IPO GMP
GREY MARKET
PREMIUM
₹
+ 2
+1% expected return
EST. LISTING
PRICE
₹141
Issue Price: ₹
139
Issue Price
₹139
Face Value
₹10
Lot Size
1,000 shares
Open Date
21 May 2026
Close Date
25 May 2026
Allotment
26 May 2026
Listing Date
29 May 2026
Exchange
BSE SME
Bio Medica Laboratories IPO Details: Price, Dates & Financials
The Bio Medica Laboratories IPO GMP strength score is 7.2 out of 10, which the dashboard rates as Good. The Bio Medica Laboratories IPO valuation is tagged Strong. The Bio Medica Laboratories IPO is subscribed 2.26 times overall so far. Amounts are calculated at the upper price band of ₹139.
IPO Analytics Dashboard
LIVE
Bio Medica Laboratories IPO GMP Insights
Valuation
Strong
Bio Medica Laboratories IPO GMP Strength Score
7
/ 10
Good
0–3 Weak
3–6 Moderate
6–8 Good
8–10 Strong
Bio Medica Laboratories IPO Category-wise Subscription
Shares offered, bid & amount
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | 15.94 | 36,000 | 574,000 |
| NII / HNI | 1.30 | 1,755,000 | 2,286,000 |
| Retail (RII) | 2.92 | 1,792,000 | 5,228,000 |
| Market Maker | — | 189,000 | — |
| Total | 2.26 | 3,583,000 | 8,088,000 |
* Amount calculated at upper price band (₹139) · ** Total includes all investor categories
Bio Medica Laboratories IPO Application Sizing
Minimum investment by category
Retail Investors ?
Min. Lots
2
Shares / Lot
2,000
Min. Investment
₹278,000
HNI Investors ?
Min. Lots
3
Min. Shares
3,000
Min. Investment
₹417,000
Bio Medica Laboratories IPO Valuation — EPS & P/E
Pre & post-issue metrics
Pre-Issue EPS ?
₹ 11
Post-Issue EPS ?
₹ 10
Pre-Issue P/E ?
13 x
Post-Issue P/E ?
13 x
Bio Medica Laboratories IPO Timeline & Key Dates
- 1 Initiation of Refund 27 May 2026
- 2 Credit of Shares to Demat 27 May 2026
Investor Interpretation
- The IPO P/E of 13x reflects a strong valuation relative to typical market ranges.
- Pre-issue EPS of ₹11 compares to post-issue EPS of ₹10 after dilution.
This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.
Bio Medica Laboratories IPO Subscription FAQs
Bio Medica Laboratories IPO is subscribed 2.26x overall (Retail 2.92x, QIB 15.94x, NII/HNI 1.30x).
The retail (RII) portion of Bio Medica Laboratories IPO is subscribed 2.92x.
Bio Medica Laboratories IPO — QIB 15.94x, NII/HNI 1.30x.
In Bio Medica Laboratories IPO, retail investors can apply for a minimum of 2 lot(s) (₹₹278,000); HNI/sNII minimum 3 lots (₹₹417,000).
Shares offered by category — QIB 36,000 shares, Retail 1,792,000 shares.
Bio Medica Laboratories IPO valuation — pre-issue EPS ₹10.67, post-issue EPS ₹10.33, pre-issue P/E 13.03, post-issue P/E 13.45.
Subscription is shares bid for divided by shares offered in that category. If 10 lakh shares are offered and 50 lakh are bid for, the category is subscribed 5 times. Final numbers are confirmed after the bidding closes.
The NII category covers investors applying for shares outside the retail investor category, while HNI commonly refers to high-value investors within the NII category. Understanding the Bio Medica Laboratories IPO's NII and HNI subscription levels helps investors assess demand for the Bio Medica Laboratories IPO and overall investor interest.
GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.